Patents by Inventor Heather Maecker

Heather Maecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
    Publication number: 20230287127
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2023
    Publication date: September 14, 2023
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
    Publication number: 20220362378
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: February 14, 2022
    Publication date: November 17, 2022
    Inventors: Heather MAECKER, Bryan IRVING
  • ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
    Publication number: 20210032345
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: April 21, 2020
    Publication date: February 4, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
    Patent number: 10646567
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
    Publication number: 20190016807
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2018
    Publication date: January 17, 2019
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
    Publication number: 20180236066
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING
  • Anti-PD-L1 antibodies, compositions and articles of manufacture
    Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
    Patent number: 9895441
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20180021431
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING
  • Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
    Patent number: 9724413
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20170107287
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: October 26, 2016
    Publication date: April 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES
    Publication number: 20160222117
    Abstract: The present application relates to nucleic acid encoding anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: September 4, 2015
    Publication date: August 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
    Publication number: 20150320859
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: December 1, 2014
    Publication date: November 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Heather MAECKER, Bryan IRVING
  • ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
    Publication number: 20150322153
    Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: November 11, 2014
    Publication date: November 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20140341902
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20140065135
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: July 30, 2013
    Publication date: March 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
    Publication number: 20130045202
    Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 24, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
    Publication number: 20130045200
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20130045201
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: BRYAN IRVING, HENRY CHIU, HEATHER MAECKER, SANJEEV MARIATHASAN, SOPHIE M. LEHAR, YAN WU, JEANNE CHEUNG
  • METHODS AND COMPOSITIONS FOR MODULATING TWEAK AND FN14 ACTIVITY
    Publication number: 20120269808
    Abstract: Agonists and antagonists which modulate the activity of TWEAK and TWEAK receptor are provided. The methods, compositions and kits of the invention may be employed in the treatment of disorders such as cancer and immune-related diseases.
    Type: Application
    Filed: November 21, 2011
    Publication date: October 25, 2012
    Applicant: Genentech, Inc.
    Inventors: AVI J. ASHKENAZI, Heather Maecker